Although the production and use of engineered nanomaterials (ENMs) is rapidly increasing, we lack sufficient knowledge regarding their capacity to induce and/or promote allergic disease. As novel ENMs are being developed and used for biomedical applications, such as drug delivery, it will be critical to understand the relationship between physicochemical properties of ENMs and possible mechanisms of immunomodulation.
INTRODUCTION
Engineered nanomaterials (ENMs) possess a high degree of functionality based on their unique physicochemical properties. These ENMs can be synthesized to have diverse chemical composition, shape, electrothermal conductance, solubility, and can be extensively modified by the addition of various surface groups. On the basis of these properties, ENMs have an extraordinary number of applications including their use as drug delivery systems, incorporation in many consumer products, and multiple uses in manufacturing processes. Types of ENMs currently being utilized can be broadly classified as carbon-based, metal, or metal oxides. As the usage of ENMs has increased so have concerns regarding their safety. Accidental exposure to ENMs may occur during manufacturing and processing in occupational settings, whereas intentional exposure will occur during the use of nanomedicines or consumer products such as cosmetics. Considerable research in animal models has demonstrated negative cardiopulmonary health effects of ENMs; however, less consideration has been given to specific interactions with the immune system while even less information exists on the potential of these materials to initiate or exacerbate allergic disease. Because of unique interactions with the immune system and the potential for these materials to act as adjuvants, it is likely that ENMs may initiate or promote the development of allergic disease. Much of the concern regarding ENM safety has been based upon data demonstrating that an ENM may be more toxic than larger particles of the same chemical composition due to their increased reactivity, surface area, particle number on a mass basis, and altered deposition profile. The same unique properties that make ENMs useful for numerous applications also may specifically result in novel immune interactions resulting in the development or exacerbation of various allergic diseases such as asthma, dermatitis, rhinitis, and others. For example, clinical trials evaluating Ferraheme, a polyglucose sorbitol carboxymethylether coated super-paramagnetic iron oxide nanoparticle, for the treatment of iron deficiency anemia in adult patients with chronic kidney disease demonstrated hypersensitivity reactions as a major safety concern [1]. To evaluate the likelihood of an ENM contributing to allergic disease, we assessed publications from the last 3 years, which focused on ENMs that are currently or proposed to be utilized as nanomedicines and/or wherein exposures may occur in occupational settings. Further, the literature search assessed cells well known to mediate allergic disease (e.g. basophils, mast cells, dendritic cells, and T cells).
IS THERE A RELATIONSHIP BETWEEN ENGINEERED NANOMATERIAL PHYSICOCHEMICAL PROPERTIES AND ALLERGIC DISEASE?
Nanomaterials have a vast array of physicochemical properties, which can be modified for specific applications. These properties include size, surface charge, shape, surface modifications, magnetism, and electrical and thermal conductivity. These diverse modifiable properties influence ENM interactions with the immune system. For example, size is an easily altered property that has been shown to alter dendritic cell uptake and antigen presentation both in vitro and in vivo [2 & ]. Specifically, 40 nm nanoparticles were determined to migrate to lymph nodes and be taken up more efficiently by dendritic cells compared with larger-sized particles. Further, the 40 nm nanoparticles were found to activate dendritic cells suggesting that size is a modifiable characteristic of ENM that can be manipulated for variations in antigen delivery. Preliminary data from our laboratory have also demonstrated the importance of size, as 20 nm silver nanoparticles were found to induce mast cell degranulation in vitro, whereas silver nanoparticles of 110 nm size did not elicit a mast cell response (unpublished data). Surface coatings also modulate immune cell responses as demonstrated by coating of superparamagnetic iron oxide nanoparticles with polylysine leading to enhanced uptake of these nanoparticles by dendritic cells in vitro [3] . To date, few studies have systematically evaluated physicochemical properties of ENMs that are responsible for immune cell activation and toxicity, which may lead to the development or exacerbation of allergic disease.
ENGINEERED NANOMATERIAL-IMMUNE CELL INTERACTIONS
The immune system is composed of a variety of effector cells and molecules whose interactions with ENM must be understood for risk assessment of these unique materials and their potential health effects. Because of their position at physiological-environmental interfaces and their role in eliminating pathogens and foreign substances, it is likely that immune cells will interact with ENMs, and that they will facilitate biological responses. Specifically, ENMs may facilitate allergic disease viaimmunoglobulin E (IgE)-dependent response and/or interactions with mast cells, basophils, dendritic cells, and T cells.
IgE is a key mediator of allergic disease by which mast cells and basophils are primed to respond to allergens. A few studies in animal models have begun to identify changes in IgE levels associated with ENM exposure. For example, utilizing a mouse model of atopic dermatitis, Hirai et al. [4] demonstrated that injections of amorphous silica nanoparticles significantly increased plasma levels of IgE, inflammatory cell infiltration, and ear thickness in a nanoparticle size-dependent manner with the smallest nanoparticles initiating the greatest effect. Oral administration of silver nanoparticles to mice has also been shown to induce an increase in circulating inflammatory cytokines and IgE levels demonstrating that different routes of exposure may facilitate allergic responses [5] . These findings demonstrate that ENMs may exacerbate an underlying allergic condition through increases in circulating IgE levels. These studies reported increases in nonspecific IgE levels; however, there is currently a lack of understanding regarding the production of allergen-specific IgE following ENM exposure. Lastly, these findings show that physicochemical
KEY POINTS
Humans are increasingly exposed to ENMs because of their incorporation into numerous consumer products and biomedical applications.
ENMs directly interact with immune cells involved in allergic disease such as mast cells and dendritic cells.
Physicochemical properties (e.g. size, charge, and surface modifications) drive ENM immune cell interactions and IgE synthesis.
ENMs may act as an adjuvant to promote allergic disease.
To ensure the safe development of ENMs for biomedical applications, it is critical we assess the potential of these novel materials to elicit allergic immune responses.
properties such as size may play a role in the allergic response to ENMs, therefore suggesting unique immune interactions of materials at the nanoscale.
Mast cells populate tissues that are exposed to the external environment and coordinate immune responses through the synthesis and release of a variety of mediators. Mast cells are well recognized for their role in facilitating allergic responses in many disease conditions through allergen cross-linking of the high affinity IgE receptor (FceRI) and subsequent release of histamine and a multitude of inflammatory mediators. Because of their location and immune regulatory role, mast cells may represent a key offtarget cell type that could contribute significantly to allergic immune responses following ENM exposure. Despite their propensity to influence a number of physiological systems, there have been only a few reports of ENM-activating mast cells. Titanium dioxide (TiO 2 ) nanoparticle exposure has been demonstrated to activate L-type Ca 2þ channels on the membranes of mast cells in vitro, which could exacerbate allergic inflammatory responses by enhancing degranulation with or without IgE sensitization [6] . Cerium oxide (CeO 2 ) nanoparticles have also been shown to activate mast cells in vitro resulting in the release of a variety of inflammatory cytokines including tumor necrosis factor-a (TNF-a), interleukin-6 (IL-6), and osteopontin [7] . Several studies [8] [9] [10] have also described the direct activation of mast cells in vitro by various metal oxide nanoparticles. Although not highly phagocytic, in-vitro studies [11, 12] of mast cells have been shown internalization of silicon dioxide and TiO 2 resulting in a reduction in degranulation possibly through interference of intracellular signaling. In contrast, the unique physicochemical properties of ENMs could be utilized for the treatment of allergic disease. For example, C60 fullerene, a spherical ENM composed of 60 carbon atoms, has been shown to inhibit mast cell-mediated anaphylaxis in mice due to their antioxidant capabilities [13] . Although the number of studies is somewhat limited, nanoparticles possess an ability to directly interact with mast cells thus supporting the need for further investigation on mast cell responses to ENMs.
Because of their relatively low abundance in circulation, basophils are an underappreciated immune cell that has a tremendous capacity for promoting the Th2 immune response [14] . Despite this, there is a significant lack of studies investigating their possible response to ENM exposure. As many nanomedicines are being developed for intravenous delivery, there exists a real possibility that basophil activation could lead to unwanted immune consequences. To date, the few studies that have examined basophil response have targeted basophils to inhibit allergic responses. For example, C60 fullerene in vitro and fullerene derivatives in vitro and in vivo have been shown to inhibit FceRI-mediated basophil degranulation and cytokine production [13, 15] . Further, it has been proposed based on in-vitro assessments that ENMs coated with antibodies for sialic acid immunoglobulin-like lectins, which are present on the surface of basophils, eosinophils, and mast cells could be utilized to inhibit their degranulation and allergic effects [16] . Although certain ENMs have shown potential for therapeutic benefit by inhibiting basophil activity it is likely that because of the vast number and diversity of ENMs being developed that some of these materials will adversely stimulate basophil responses. Stimulation of basophils would likely propagate Th2 responses resulting in an exacerbation of underlying allergic conditions. Dendritic cells function by capturing and presenting antigen thus bridging the innate and adaptive immune system. Their ability to capture antigen makes them a likely target in the uptake of ENMs, whereas their strong antigen presenting capability makes these cells a likely target for either immunosuppression or stimulation leading to immunomodulation. In fact, most studies [17] [18] [19] of dendritic cells have focused on enhancing vaccine responses through the use of various nanoparticle formations. However, the same properties of nanomaterials that enhance vaccine responses may also pose a challenge to nanomedicines in which the intended result is likely not immune stimulation. A number of studies have demonstrated the ability of dendritic cells to phagocytose ENMs. For example, a recent study [20] of gold nanoparticles has shown that 18% of particles that reach the spleen in a mouse model are taken up by dendritic cells. In an in-vitro assessment of quantum dot uptake, it was shown that differentiation of monocytes to dendritic cells significantly increased cellular uptake six-fold [21] . These findings demonstrate that the dendritic cell may be a site of nanoparticle accumulation, which could be used therapeutically, but also may pose some additional challenges to the safe use of nanotechnology.
Multiwalled carbon nanotubes have been shown to have immunomodulatory activity by decreasing the capacity of peripheral blood monocytes collected from humans to differentiate into functional dendritic cells [22] . These findings suggest that exposure to ENMs may cause cytotoxicity to dendritic cells, and it is likely that they may be immunosuppressive although inhibiting monocyte differentiation. These ENM-induced changes in dendritic cell immune response and cytotoxicity are probably related to internalization of ENMs and intracellular alterations in cell signaling and induction of apoptotic pathways. Most importantly, a few studies have found that the treatment of dendritic cells with ENMs is immunomodulatory. Schanen et al. [23 && ] demonstrated that exposure of dendritic cells to CeO 2 nanoparticles caused a Th2-type response from T cells following antigen presentation as demonstrated by increased cytokine production of IL-4, IL-5, and IL-10, whereas exposure of dendritic cells to TiO 2 nanoparticles was found to elicit a Th1-type response as demonstrated by increased cytokine production of IL-2, interferon-g, and TNF-a. Taken together, exposure to ENMs alters dendritic cell function, which may lead to downstream effects on the immune system such as impairment or stimulation of T cell proliferation and activation.
An in-vitro evaluation of the toxicity induced by different porous silicon nanoparticles across multiple cell types including T cells, monocytes, macrophages, and B cells demonstrated that T cells were the most sensitive [24] . Specifically, T cells demonstrated increased morphological changes, adenosine triphosphate depletion, and decreased proliferation compared with other cell types following exposure. An in-vitro examination of T cell responses to cobalt nanoparticles demonstrated DNA damage, oxidative stress, and cytotoxicity following exposure. These findings suggest that direct interactions with ENMs can induce T cell toxicity [25] . Recently, we compared the immune response of mice to intravenous exposure of multiwalled carbon nanotubes and graphene nanosheets, two carbon-based materials but of varying shapes and surface area [26 & ]. In these studies, we observed a Th2 immune response in the lungs and spleens of mice treated with graphene nanosheets once again suggesting physicochemical properties dictate immune outcomes. Additional in-vivo studies have demonstrated that pulmonary exposure of C57BL/6 mice to single-walled carbon nanotubes and carbon nanofibers decreases the proliferation of T cells ex vivo 7 and 28 days following exposure, respectively [27] . These findings demonstrate in-vivo responses to carbon-based nanoparticles, which have longlasting immunological effects that could impair immune function. Overall, the evaluation of T cell responses to ENM show an in-vivo preference for initiating Th2-type immune responses, which can lead to increases in IgE and the progression toward an allergic state.
ADDITIONAL MECHANISMS BY WHICH ENGINEERED NANOMATERIAL COULD PROMOTE ALLERGIC RESPONSES
An unexplored area of research that may evoke allergic immune responses is the interaction and structural alteration of macromolecules on the surface of ENMs. Upon introduction into a physiological environment, ENMs associate with a variety of macromolecules including proteins and lipids forming a 'corona'. This corona is a dynamic entity with macromolecules associating and dissociating constantly. The addition of these macromolecules creates a unique entity, which can modify the activity, distribution, clearance, and toxicity of an ENM. Studies [28, 29] have demonstrated that following association with an ENM these macromolecules undergo conformational changes, which could alter immune responses. Conformationally, altered proteins that are released from or remain bound to ENMs could alter antigen presentation by dendritic cells as an example. Further, presentation of self or nonself-peptides that have been altered due to biophysical interactions with an ENM may possess the potential to initiate autoimmune or allergic immune responses.
A major focus of biomedical nanotechnology research has been the utilization of nanoparticles as adjuvants for enhancing immune responses to vaccines. It has been well established that many larger sized particles can act as an adjuvant thereby, exacerbating allergic responses. Because of the unique properties of ENMs such as size, surface area, and bioavailability, it is likely that materials of the same composition, but at the nanoscale may possess enhanced adjuvant-like activity. Many toxicity studies have demonstrated this principle by showing that materials of the same composition have increased toxicity at the nanoscale. Limited data currently exist regarding the adjuvant potential of ENMs; however, the current data available suggest that ENMs likely have adjuvant capacity. Examination of the adjuvant capacity of carbon nanofibers and nanotubes utilizing both an injection and intranasal model found both types of ENMs to have adjuvant capacity [30 && ]. Specifically, exposure to both carbon-based ENMs was found to increase serum ovalbumin-specific IgE, IgG1, and IgG2a levels compared with ovalbumin alone. Interestingly, in the intranasal model, carbon nanotubes produced an enhanced IgE response compared with carbon nanofibers, again suggesting that physicochemical properties of these materials have a large influence on immunogenicity. Another example using polyethylene glycol-coated amorphous silica nanoparticles demonstrated concentration-dependent allergic airway adjuvant-like effects resulting from coexposure with ovalbumin [31] . Specifically, this consisted of increased ovalbumin-specific serum IgE levels, airway eosinophilia, Th2, and Th17 cytokines. Interestingly, these adjuvant-like effects were found at doses lower than was required to cause an innate immune response. Silver nanoparticles also have a capacity to function as an adjuvant resulting in exacerbation of Th2 immune responses compared with ovalbumin or bovine serum albumin alone [32] . These findings suggest that coexposures of ENMs and allergens will promote allergic responses, and that this may occur at lower doses than required to stimulate an innate immune response.
CONCLUSION
Currently, there is a significant lack of knowledge to understand the risk of allergic disease resulting from ENM exposures. The limited research to date regarding the direct interactions of ENMs with the immune system, however, suggests that this may be an area of concern. Because of the large number of ENMs being developed and produced; and the increased risk of human exposure, their ability to initiate or exacerbate allergic diseases requires assessment. Lastly, ENMs may induce allergic responses via multiple scenarios that are related to their unique physicochemical properties.
